From CNBC:

Eli Lilly’s shares rose as their Alzheimer’s drug slowed disease progression in a final-stage trial, aiming for US approval. However, the FDA postponed a decision on the drug to convene an advisory meeting. Eli Lilly faces competition from Biogen and Eisai in developing Alzheimer’s treatments targeting amyloid plaque buildup.



Read more at CNBC: Eli Lilly Alzheimer’s drug FDA approval delayed